A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients

Phase 1TerminatedNCT03670888

JHL Biotech, Inc.1 enrolled

Overview

This is a multicenter, randomized, double-blind, parallel group study to compare the PK, safety, tolerability, immunogenicity and PD of JHL1101 vs Rituxan in subjects with CD20-positive B cell lymphoma. The study duration is 13 weeks. Approximately 128 eligible subjects will be randomized in a 1:1 ratio to receive either JHL1101 (n=64) or Rituxan (n=64). Each subject will receive one intravenous (IV) infusions of the investigational product (IP) at the dose of 375mg/m2 on Day 1. Assessments of PK, safety, tolerability, immunogenicity, PD, and efficacy will be collected over the following 13-week period.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

B Cell Lymphoma

Interventions

JHL1101

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. CD20-positive B-cell lymphoma. 2. Obtained CR (complete remission) or CRu (uncertain complete remission) after the prior therapy 3. 18 years to 75 years 4. Signed an informed consent 5. Adequate organ function, including the following * Absolute neutrophil count (ANC) ≥ 1,500/uL; platelet count ≥ 75,000/uL; hemoglobin ≥ 8 g/dL * Total bilirubin ≤ 1.5 times the upper limit of normal (ULN), aspartate transaminase (AST) and/or alanine aminotransferase (ALT) ≤ 2.5 times ULN * Serum creatinine ≤ 1.5 times the ULN 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 7. Chemotherapy: must not have received within 8 weeks of entry onto this study 8. Radiotherapy: must not have received within 4 weeks of entry onto this study 9. Recovery (to baseline or to Grade 1 or less) from prior treatment-related toxicities except alopecia 10. Aagreement to practice contraception 11. More than 6 months life expectancy. Exclusion Criteria: 1. Received any investigational drug within 28 days prior to study enrollment 2. Received blood transfusion or any therapies with erythropoietin (EPO), granulocyte-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) within 14 days prior to study enrollment 3. Received previous immunotherapy 4. Received or plan to receive a live vaccine within 28 days of study enrollment 5. Major surgery within 28 days of study enrollment 6. Received systemic steroid therapy with 28 days of study enrollment 7. Received or plan to receive the hematopoietic cell transplant 8. History of gastrointestinal perforation and/or fistula within 6 months prior to study enrollment 9. Known allergic reactions against monoclonal antibody or rituximab. 10. Received rituximab or other anti-CD20 monoclonal antibody 11. Blood concentration of rituximab \> 10 ug/mL during screen visit 12. Human immunodeficiency virus (HIV) positive 13. Hepatitis C virus (HCV) antigen and antibody positive 14. Hepatitis B virus surface antigen (HBsAg) positive 15. Body Mass Index (MBI) ≥ 28 kg/m2

Locations (2)

First Hospital of Shanxi Medical University

Taiyuan, Shanxi, China

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Tianjin, Tianjin Municipality, China

Outcomes

Primary Outcomes

AUC0~t

Area under the concentration-time curve (AUC) from time 0 (predose) of the first infusion on Day 1 to the last quantifiable concentration

Time frame: 91 days

Secondary Outcomes

AUC0-∞

AUC from time 0 of the first infusion on Day 1 extrapolated to infinity

Time frame: 91 days

Cmax

Maximum concentration after infusion

Time frame: 91 days